lutikizumab + risankizumab

**Lutikizumab + risankizumab** is an experimental combination therapy composed of two monoclonal antibodies: lutikizumab (an interleukin-1α and interleukin-1β inhibitor) and risankizumab (a selective interleukin-23 p19 subunit inhibitor). Each component targets a distinct pathway involved in autoimmune and inflammatory diseases. The combination is being studied primarily for psoriatic arthritis, with the aim of optimizing therapeutic efficacy by inhibiting key cytokine signaling pathways involved in inflammation and immune regulation[1][10]. - **Lutikizumab** is a dual-variable domain immunoglobulin that neutralizes both interleukin-1α and interleukin-1β, aiming to disrupt inflammatory processes mediated by these cytokines[4][7]. - **Risankizumab** blocks the IL-23/Th17 axis via highly selective binding to the p19 subunit of interleukin-23, decreasing pathogenic Th17-mediated inflammation[1][2]. Primary indications under clinical investigation include psoriatic arthritis[1][10], though lutikizumab has also undergone study in hidradenitis suppurativa and is being considered in other inflammatory diseases.

Brand names

Skyrizi

Other names

lutikizumab + risankizumab